• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by MediWound Ltd.

    10/23/24 2:57:43 PM ET
    $MDWD
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MDWD alert in real time by email
    SC 13G/A 1 rosalind_mdwd_13ga4_sep2.htm Schedule 13G

     


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G/A

    (Amendment No: 04)

    Under the Securities Exchange Act of 1934

    MEDIWOUND LTD.

    (Name of Issuer)

    Common Shares

    (Title of Class of Securities)

    M68830104

    (CUSIP Number)

    September 30, 2024

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ¨  Rule 13d-1(b)
    x  Rule 13d-1(c)
    ¨  Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. M68830104

     

    13G/A

     

    Page 2 of 9 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Rosalind Advisors, Inc.

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    ONTARIO, CANADA

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5.

     

    SOLE VOTING POWER  
     
    0

     

    6.

     

    SHARED VOTING POWER
     
    628,050 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

    7.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    8.

     

    SHARED DISPOSITIVE POWER
     
    628,050 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

     

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    628,050 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.8%1

     

     

    12.

     

    TYPE OF REPORTING PERSON (see instructions)

    CO

     

     

     

     

     

     

     


    1 This percentage is calculated based upon 10,786,423 shares of the Issuer’s common stock outstanding as of August 15, 2024 in accordance with F-3 filed on Aug 29, 2024.


     

    NYC#: 139632.2


     


    CUSIP No. M68830104

     

    13G/A

     

    Page 3 of 9 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Steven Salamon

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    ONTARIO, CANADA

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5.

     

    SOLE VOTING POWER
     
    0

     

    6.

     

    SHARED VOTING POWER
     
    628,050 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

    7.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    8.

     

    SHARED DISPOSITIVE POWER
     
    628,050 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

     

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    628,050 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.8%

     

     

    12.

     

    TYPE OF REPORTING PERSON (see instructions)

    IN

     

     

     

     

     

     

     

     

    CUSIP No. M68830104

     

    13G/A

     

    Page 4 of 9 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Gilad Aharon

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    ONTARIO, CANADA

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5.

     

    SOLE VOTING POWER
     
    0

     

    6.

     

    SHARED VOTING POWER
     
    628,050 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

    7.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    8.

     

    SHARED DISPOSITIVE POWER
     
    628,050 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

     

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    628,050 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.8%

     

     

    12.

     

    TYPE OF REPORTING PERSON (see instructions)

    IN

     

     

     

     

     

     

     

     

     

     

     

     

     

    CUSIP No. M68830104

     

    13G/A

     

    Page 5 of 9 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Rosalind Master Fund L.P.

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    CAYMAN ISLANDS

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    5.

     

    SOLE VOTING POWER
     
    0

     

    6.

     

    SHARED VOTING POWER
     
    628,050 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

    7.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    8.

     

    SHARED DISPOSITIVE POWER
     
    628,050 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

     

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    628,050 shares of Common Stock

    163,265 shares of Common Stock issuable upon exercise of warrants

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.8%

     

     

    12.

     

    TYPE OF REPORTING PERSON (see instructions)

    PN

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    CUSIP No. M68830104

     

    13G/A

     

    Page 6 of 9 Pages

     

     

     

     

     

    Item 1.

     

    (a)

    Name of Issuer: MEDIWOUND LTD.

     

     

     

     

    (b)

    Address of Issuer’s Principal Executive Offices
    42 Hayarkon Street, Yavne, Israel 8122745

     

     

     

    Item 2.

     

    (a)

    Name of Person Filing

    Rosalind Advisors, Inc. (“Advisor” to RMF)

    Rosalind Master Fund L.P. (“RMF”)

    Steven Salamon (“President”)

    Steven Salamon is the portfolio manager of the Advisor which advises RMF.

    Gilad Aharon is the portfolio manager and member of the Advisor which advises RMF.

     

     

     

     

     

    (b)

    Address of the Principal Office or, if none, residence
    Rosalind Advisors, Inc.

    15 Wellesley Street West

    Suite 326

    Toronto, Ontario

    M4Y 0G7 Canada

     

    Rosalind Master Fund L.P.

    P.O. Box 309

    Ugland House, Grand Cayman

    KY1-1104, Cayman Islands

     

    Steven Salamon

    15 Wellesley Street West

    Suite 326

    Toronto, Ontario

    M4Y 0G7 Canada

     

    Gilad Aharon

    15 Wellesley Street West

    Suite 326

    Toronto, Ontario

    M4Y 0G7 Canada

     

     

     

     

    (c)

    Citizenship
    Rosalind Advisors, Inc.: Ontario, Canada

    Rosalind Master Fund L.P.: Cayman Islands

    Steven Salamon: Ontario, Canada

    Gilad Aharon: Ontario, Canada

     

     

     

     

    (d)

    Title of Class of Securities
    Common Stock

     

     

     

     

    (e)

    CUSIP Number
    M68830104


     

    NYC#: 139632.2


     


     

     

     

     

     

    CUSIP No. M68830104

     

    13G/A

     

    Page 7 of 9 Pages

     

     

     

     

     

    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)

    ¨

    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

     

     

     

     

    (b)

    ¨

    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

     

     

     

     

    (c)

    ¨

    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

     

     

     

     

    (d)

    ¨

    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

     

     

     

     

    (e)

    ¨

    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     

     

     

     

     

    (f)

    ¨

    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

     

     

     

     

    (g)

    ¨

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

     

     

     

     

    (h)

    ¨

    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

     

     

     

     

    (i)

    ¨

    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

     

     

     

     

    (j)

    ¨

    Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

     

     

     

    Item 4.  Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

     

     

     

     

     

    (a)

     

    Amount beneficially owned:  

     

    The information as of the date of the event which requires filing of this statement required by Items 5(a) – (c) is set forth in Rows 7 – 13 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.  The percentage set forth in Row 13 of the cover page for each Reporting Person is based upon 10,786,423 shares of the Issuer’s common stock outstanding as of August 15, 2024 in accordance with F-3 filed on August 29, 2024.

    Rosalind Master Fund L.P. is the record owner of 628,050 shares of common stock and 163,265 shares of Common Stock issuable upon exercise of warrants.

    Rosalind Advisors, Inc. is the investment advisor to RMF and may be deemed to be the beneficial owner of shares held by RMF.  Steven Salamon is the portfolio manager of the Advisor and may be deemed to be the beneficial owner of shares held by RMF.  Notwithstanding the foregoing, the Advisor and Mr. Salamon disclaim beneficial ownership of the shares.  

     

     

     

     

     

     

    (b)

     

    Percent of class:  

    Rosalind Advisors, Inc. –  5.8%

    Rosalind Master Fund L.P. –  5.8%

    Steven Salamon –  5.8%

    Gilad Aharon –  5.8%

     

     

     

     

     


     

    NYC#: 139632.2


     


     

     

     

     

     

    CUSIP No. M68830104

     

    13G/A

     

    Page 8 of 9 Pages

     

     

     

     

     

     

    (c)

     

    Number of shares as to which the person has:  

     

     

     

    (i)

    Shared power to vote or to direct the vote  

    Rosalind Advisors, Inc. –  628,050 shares of Common Stock

    Rosalind Master Fund L.P. – 628,050 shares of Common Stock

    Steven Salamon – 628,050 shares of Common Stock

    Gilad Aharon - 628,050 shares of Common Stock

     

     

     

     

     

     

     

     

    (ii)

    Sole power to dispose or to direct the disposition of  – 0

     

     

     

     

     

     

     

     

    (iii)

    Shared power to dispose or to direct the disposition of  

    Rosalind Advisors, Inc. – 628,050 shares of Common Stock

    Rosalind Master Fund L.P. – 628,050 shares of Common Stock

    Steven Salamon – 628,050 shares of Common Stock

    Gilad Aharon - 628,050 shares of Common Stock

     

     

     

     

     

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

    Item 5.  Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

    Instruction. Dissolution of a group requires a response to this item.

    Item 6.  Ownership of More than Five Percent on Behalf of Another Person.

    Item 7 – 9.  Not Applicable


     

    NYC#: 139632.2


     


     

     

     

     

     

    CUSIP No. M68830104

     

    13G/A

     

    Page 9 of 9 Pages

     

     

     

     

     

    Item 10.  Certification.

     

     

     

     

     

     

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

     

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    10/23/2024

    Date

     

     

    Signature

     

    Steven Salamon/President Rosalind Advisors, Inc.

    Name/Title

     

     

    Exhibit A

    Joint Filing Agreement

     

    The undersigned hereby agree that this Statement on Schedule 13G/A with respect to the beneficial ownership of shares of Common Stock of MEDIWOUND LTD. is filed jointly, on behalf of each of them.

     

     

    Rosalind Advisors, Inc.

    By: _____________________________

    Name: Steven Salamon

    Title: President

     

    Rosalind Master Fund L.P.

    By: _____________________________

    Name: Mike McDonald

    Title: Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)

     

    By: _____________________________

    Name: Steven Salamon


     

    NYC#: 139632.2

    Get the next $MDWD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDWD

    DatePrice TargetRatingAnalyst
    5/2/2025$25.00Buy
    Alliance Global Partners
    2/28/2025$39.00Buy
    Craig Hallum
    7/16/2024$25.00 → $30.00Buy
    Maxim Group
    12/22/2022$11.00Buy
    Maxim Group
    7/18/2022$7.00Outperform
    Oppenheimer
    8/17/2021$10.00 → $9.00Buy
    Aegis Capital
    8/11/2021$7.00 → $6.50Buy
    HC Wainwright & Co.
    More analyst ratings

    $MDWD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MediWound to Report First Quarter 2025 Financial Results

      YAVNE, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 21, 2025. Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates. Dial-in and call details are as follows: Conference Call & Webcast DetailsToll-Free:1-844-676-8833Israel:1-80-921-2373International:1-412-634-6869Webcast:Click HERE   To access the call, participan

      5/5/25 8:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

      Presentations at WHS and SAWC to highlight EscharEx's mechanism of action, preclinical advantages over SANTYL®, and new data in treating VLUs and DFUs Findings reinforce the ongoing Phase III study in VLUs and support the planned DFU trial strategy YAVNE, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will present 10 scientific abstracts—including both oral and poster presentations—at two of the world's premier wound care conferences: the Wound Healing Society (WHS) and the Symposium on Advanced Wound Care (SAWC) Spring 2025, taking place April 30

      4/28/25 8:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue for 2024; $24 million projected for 2025; $44 million in cash as of Year-End 2024 Conference call today, March 19 at 8:30am Eastern Time YAVNE, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update. "2024 was a pivotal year for MediWound, marked by strong execution, clinica

      3/19/25 7:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MDWD
    SEC Filings

    See more
    • SEC Form 6-K filed by MediWound Ltd.

      6-K - MediWound Ltd. (0001593984) (Filer)

      4/7/25 4:04:11 PM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 424B3 filed by MediWound Ltd.

      424B3 - MediWound Ltd. (0001593984) (Filer)

      3/28/25 4:05:31 PM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form EFFECT filed by MediWound Ltd.

      EFFECT - MediWound Ltd. (0001593984) (Filer)

      3/28/25 12:15:23 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MDWD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

      Submission status for MEDIWOUND, LTD's drug NEXOBRID (SUPPL-10) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 08/15/2024. Application Category: BLA, Application Number: 761192, Application Classification:

      8/16/24 4:36:54 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

      Submission status for MEDIWOUND, LTD's drug NEXOBRID (ORIG-1) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761192, Application Classification:

      12/30/22 4:38:06 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • FDA Approval for NEXOBRID issued to MEDIWOUND, LTD

      Submission status for MEDIWOUND, LTD's drug NEXOBRID (SUPPL-1) with active ingredient ANACAULASE-BCDB has changed to 'Approval' on 12/28/2022. Application Category: BLA, Application Number: 761192, Application Classification:

      12/29/22 1:11:07 PM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MDWD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by MediWound Ltd.

      SC 13G/A - MediWound Ltd. (0001593984) (Subject)

      11/14/24 7:55:11 PM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13G/A filed by MediWound Ltd.

      SC 13G/A - MediWound Ltd. (0001593984) (Subject)

      10/23/24 2:57:43 PM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by MediWound Ltd.

      SC 13G - MediWound Ltd. (0001593984) (Subject)

      10/1/24 8:23:53 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care

    $MDWD
    Leadership Updates

    Live Leadership Updates

    See more

    $MDWD
    Financials

    Live finance-specific insights

    See more

    $MDWD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer

      YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief Operating Officer and Chief Commercial Officer effective as of December 1, 2023. Dr. Hess will lead and oversee all operational and commercial activities at MediWound. "We are delighted to welcome Shmulik, a distinguished industry executive, to our team. Dr. Hess joins MediWound during a crucial phase of expansion as we diligently implement our global strategy. Given Shmulik's outstanding track record in international o

      11/21/23 7:00:00 AM ET
      $ENLV
      $MDWD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products
    • MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe

      YAVNE, Israel, and DENKENDORF, Germany, Nov. 08, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, and PolyMedics Innovations (PMI), an innovative biomaterials company specializing in effective wounds treatment, today announced an agreement for the promotion of NexoBrid® in Germany, Austria, Belgium, the Netherlands and Luxemburg. Feedback from key opinion leaders and customers indicates that NexoBrid, a non-surgical solution for eschar removal in burns, is a perfect complement to PMI's existing product line, including SUPRATHEL®, NovoSorb® BTM, and SUPRA SDRM®. Along wit

      11/8/23 7:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer

      YAVNE, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully integrated biopharmaceutical company specializing in next-generation biotherapeutic solutions for tissue repair and regeneration, is pleased to announce the appointment of Ms. Hani Luxenburg as its new Chief Financial Officer, effective May 14, 2023. Ms. Luxenburg will replace Mr. Boaz Gur-Lavie, who has served as MediWound's Chief Financial Officer for the past four years. Mr. Gur-Lavie will remain with the Company through July 31, 2023 to ensure an orderly transition. With over 20 years of progressive leadership experience managing financial and accounting operations, Ms. Luxenburg joins MediWound wi

      3/16/23 7:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MediWound to Report First Quarter 2025 Financial Results

      YAVNE, Israel, May 05, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will report financial results for the first quarter ended March 31, 2025 on Wednesday, May 21, 2025. Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates. Dial-in and call details are as follows: Conference Call & Webcast DetailsToll-Free:1-844-676-8833Israel:1-80-921-2373International:1-412-634-6869Webcast:Click HERE   To access the call, participan

      5/5/25 8:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers Expanded strategic research collaborations with industry leaders, now including Kerecis $20 million in revenue for 2024; $24 million projected for 2025; $44 million in cash as of Year-End 2024 Conference call today, March 19 at 8:30am Eastern Time YAVNE, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update. "2024 was a pivotal year for MediWound, marked by strong execution, clinica

      3/19/25 7:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • MediWound to Report Fourth Quarter and Full Year 2024 Financial Results

      YAVNE, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2024 on Wednesday, March 19, 2025. Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates. Dial-in and call details are as follows: Conference Call & Webcast DetailsToll-Free:  1-833-630-1956Israel: 1-80-921-2373International: 1-412-317-1837Webcast: Click HERE    To access the call, partici

      3/3/25 8:00:00 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Alliance Global Partners initiated coverage on MediWound with a new price target

      Alliance Global Partners initiated coverage of MediWound with a rating of Buy and set a new price target of $25.00

      5/2/25 8:15:09 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Craig Hallum initiated coverage on MediWound with a new price target

      Craig Hallum initiated coverage of MediWound with a rating of Buy and set a new price target of $39.00

      2/28/25 7:39:12 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care
    • Maxim Group reiterated coverage on MediWound with a new price target

      Maxim Group reiterated coverage of MediWound with a rating of Buy and set a new price target of $30.00 from $25.00 previously

      7/16/24 8:08:28 AM ET
      $MDWD
      Medicinal Chemicals and Botanical Products
      Health Care